Prosecution Insights
Last updated: April 19, 2026

Nanjing Anji Biological Technology Co. Ltd.

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18003113 ANTI-HMMW ANTIBODY, COMPOSITION COMPRISING SAME, AND NUCLEIC ACID MOLECULE ENCODING SAME, AND USE THEREOF STONEBRAKER, ALYSSA RAE 1642 Non-Final OA Dec 22, 2022
17767397 POLYPEPTIDES RV3 AND RV4 HAVING ANTI-AGING FUNCTION AND APPLICATIONS THEREOF COFFA, SERGIO 1658 Final Rejection Apr 07, 2022

Managing Nanjing Anji Biological Technology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month